Nebivololo E Idroclorotiazide Accord (Hydrochlorothiazide, Nebivolol)

Nebivolol, the active ingredient in Nebivololo E Idroclorotiazide Accord, is a beta‑blocker presented as an oral tablet for oral use. It treats hypertension, often in combination with hydrochlorothiazide, and is prescribed for adult patients who need effective blood‑pressure control. Nebivolol works together with the thiazide diuretic to lower vascular resistance and reduce plasma volume.

GNH USA supplies Nebivololo E Idroclorotiazide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol/Hydrochlorothiazide is used to manage high blood pressure and related cardiovascular risk factors. - Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular events. - Secondary hypertension: assists in controlling blood pressure when caused by other medical conditions. - Hypertension with fluid retention: combines beta‑blockade and diuresis to manage both pressure and excess fluid.

Nebivolol/Hydrochlorothiazide may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate discomfort. - Dizziness or light‑headedness: especially on standing. - Fatigue: general tiredness. - Increased urination: due to diuretic effect. - Electrolyte imbalance: low potassium or sodium. - Cough: occasional irritation of the airway.

Serious or Rare Side Effects: - Severe hypotension: dangerously low blood pressure. - Bradycardia: markedly reduced heart rate. - Acute kidney injury: sudden decline in renal function. - Hyperglycaemia: elevated blood glucose levels. - Allergic reactions: rash, swelling, or anaphylaxis. - Electrolyte disturbances: severe hyponatraemia or hypokalaemia.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust dosage if needed. - Hepatic disease: use with caution in patients with liver dysfunction. - Diabetes mellitus: monitor blood glucose as thiazides may raise glucose levels. - Electrolyte disorders: check serum potassium and sodium regularly. - Concomitant antihypertensives: avoid excessive blood‑pressure lowering. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Nebivolol/Hydrochlorothiazide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective β‑blockers: additive bradycardia and hypotension. - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - NSAIDs: can reduce diuretic efficacy and impair renal function. - Lithium: thiazide may increase lithium concentrations. - Antidiabetic agents: thiazide may elevate blood glucose, requiring dose adjustment.